The Medicines and Healthcare products Regulatory Agency (MHRA) has been officially designated as a WHO-Listed Authority (WLA) by the World Health Organization, marking a pivotal achievement for UK life sciences and global health. This recognition affirms MHRA’s adherence to the highest international standards in regulating medical products, placing it amongst the world’s most trusted regulatory bodies, alongside Health Canada and Japan’s MHLW/PMDA.
The status enhances MHRA’s role in advancing the UK’s strategic vision under the Life Sciences Sector Plan and reinforces the nation’s position as a global science and regulatory hub. It also supports the ambitions of the 10-Year Health Plan for England and its associated three shifts: transitioning care from hospitals to communities, accelerating digital transformation, and prioritising preventive health approaches.
Lawrence Tallon, MHRA Chief Executive, described the WLA designation as a “proud moment,” emphasising the agency’s ongoing dedication to regulatory excellence, innovation, and global collaboration.
